Skip to main content
Fig. 2 | Radiation Oncology

Fig. 2

From: Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis

Fig. 2

Pooled ORR for all patients (a), ERT (b) and ECRT (c) groups; pooled LCR for all patients, 1-year LCR (d) and 2-year LCR (e). ORR: objective response rates; ERT: endostatin combined with radiotherapy alone; ECRT: endostatin combined with concurrent chemoradiotherapy; LCR: local control rates

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us